An interventional study of SELUTION SLR™ 018 DEB and Plain (Uncoated) Balloon Angioplasty (PTA) in Peripheral Arterial Disease and Superficial Femoral Artery Stenosis, sponsored by M.A. Med Alliance S.A.. Active, not recruiting at 34 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by M.A. Med Alliance S.A. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 479 studies in Peripheral Arterial Disease with a site in United States — 82 open to participants now, 101 under way, 10 of them phase 3. Peripheral Arterial Disease · United States.
Among the 479 studies in Peripheral Arterial Disease with a site in United States, this one is the 42nd largest by enrollment of the 373 interventional ones that give a count, is one of 20 that started in 2022, is one of 217 with no phase, reaches primary completion later than 20 of the 100 other live ones, and was the 377th registered.
1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.
Browse Peripheral Arterial Disease studies →82 of the 479 studies in Peripheral Arterial Disease with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States, Japan, United Kingdom
Ages 18+
Shanghai CureGene Pharmaceutical Co., Ltd. · Sites in United States
Ages 18–55 · Healthy volunteers
University of Tennessee Graduate School of Medicine · Sites in United States
Ages 18+
Cook Research Incorporated · Sites in United States
Ages 18+
University of Nebraska · Sites in United States
Ages 19+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
479 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 49 · Phase 2 65 · Phase 3 35 · Phase 4 25
First in 1992; this study’s year is marked. 20 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 300 is above the median of 70 across 927 interventional studies indexed under Peripheral Arterial Disease.
Median enrollment 64 across the 373 interventional studies, 125 across the 103 observational. Of the 335 that completed or were terminated, 155 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
189 of 479 have an industry lead sponsor. The 10 most frequent:
M.A. Med Alliance S.A. is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
M.A. Med Alliance S.A. has 4 studies filed under Peripheral Arterial Disease — fewer than ten, so there is no comparison to draw.
36 of the studies in Peripheral Arterial Disease with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04794530Phase 3Northwestern UniversityThe COCOA-PAD II Trial | 2026-12-31 |
| NCT05132439Phase 3VA Office of Research and DevelopmentMetfOrmin BenefIts Lower Extremities With Intermittent Claudication | 2027-02-28 |
| NCT07639853Medtronic EndovascularCase-Specific Health Care Professional Clinical Survey for Concerto Versa™ Detachable Coils | 2026-11 |
| NCT06321575Nipro Vascular Innovations Americas, IncThe Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial) | 2026-11 |
| NCT05916950Philips Clinical & Medical Affairs GlobalThe THOR IDE Study | 2026-12 |
Add all 36 to your calendar (.ics) → With an account.
Among the 479 studies in Peripheral Arterial Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to demonstrate the safety and efficacy of the SELUTION SLR™ 018 DEB compared to plain (uncoated) balloon angioplasty in the treatment of peripheral arterial disease (PAD) in the superficial femoral artery (SFA) and proximal popliteal artery (PPA).
Prospective, multi-center, single blinded, 2:1 randomized, controlled, superiority clinical trial.
This study will enroll up to 300 randomized subjects, and up to 20 subjects in a parallel pharmacokinetic (pK) sub study, at up to 60 clinical sites in the United Stated (US), Europe (EU) and Asia. A minimum of 50% of randomized subjects will be enrolled in the US. No more than 45 subjects (15% of the total randomized cohort) can be enrolled in the randomized cohort at any single investigational site.
Randomized Cohort:
Up to 300 subjects who meet all eligibility criteria will be randomized 2:1 by permuted block method (stratified by site and adjunctive lesion preparation) to one of two treatment arms:
Pharmacokinetic (pK) Sub-study:
The pK substudy is a parallel registry consisting of up to 20 additional consecutive subjects meeting all eligibility criteria treated with the SELUTION DEB recruited at select study sites. The separate PK substudy protocol details the schedule of evaluations and blood draws to characterize the pK plasma profile of sirolimus.
Clinical Inclusion Criteria:
Angiographic Inclusion Criteria:
Angiographic evidence that the target lesion consists of either a de novo lesion or a non-stented restenotic lesion, or a combination of both, that meets one of the following criteria:
A. A stenosis of 70-99% with lesion length between ≥3cm and \<20cm by visual estimation.
B. A total (100%) occlusion with lesion length between ≥3cm and ≤10cm by visual estimation.
C. A combination lesion (stenosis and total occlusion) must have a total lesion length between ≥3cm and \<20cm by visual estimation with an occluded segment that is ≤10cm by visual estimation.
D. If multiple lesions are to be treated, then only 2 lesions may be included. The total combination of lengths must be between ≥3cm and \< 20cm by visual estimation, and there must be at least 5 cm of artery that is not to be treated between them.
Patent arterial inflow (common iliac, external iliac, common femoral and profunda femoris arteries, and the proximal 2 cm of the SFA) free from significant lesion (defined as ≥50% stenosis) as confirmed on angiography.
Note: Where required, inflow iliac arteries (common and external iliac arteries only) must be successfully treated during the index procedure. Completion angiography must confirm successful treatment of inflow disease (≤30% residual stenosis, no distal embolization, and no Grade C or greater dissection ) prior to pre-dilation and randomization of the target lesion(s). Drug-eluting devices are not allowed for treatment of the occluded inflow iliac arteries.
Note: Treatment of outflow disease is permitted during the index procedure. Drug-eluting devices are not allowed for outflow treatment.
PK Sub-Study Inclusion Criteria:
Subjects must meet all of the main protocol inclusion criteria to participate in the PK sub-study. Subjects must also meet the following additional PK sub-study inclusion criteria:
1. Subject is willing and able to provide informed consent for the PK sub-study and comply with the PK sub-study procedures and required follow-up evaluations.
Clinical Exclusion Criteria:
Angiographic Exclusion Criteria:
PK Sub-Study Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment with Selution SLR drug eluting balloon to apply long term (\>90 days) local treatment with sirolimus
Device: SELUTION SLR™ 018 DEB
Opening artery only by dilatation with an temporary inserted and inflated balloon.
Device: Plain (Uncoated) Balloon Angioplasty (PTA)
a non-surgical procedure that uses a catheter to inflate a drug-eluting balloon to open up above the-knee arteries that have been narrowed due to peripheral arterial disease.
a non-surgical procedure that uses a catheter to inflate a commercially available, non-drug-eluting balloon to open up above the-knee arteries that have been narrowed due to peripheral arterial disease.
Primary Efficacy Endpoint
The primary efficacy endpoint is primary patency of the target lesion defined as freedom from ALL of the following outcomes evaluated at 12 months post procedure: * Clinically driven target lesion revascularization (CD-TLR, defined as re-intervention of target lesion(s) due to recurrent, persistent, or worsening symptoms and angiographic restenosis (≥ 50% diameter stenosis) of target lesion by ACL measurement) and * Restenosis as determined by core lab adjudicated duplex ultrasound peak systolic velocity ratio of \>2.4 or occlusion of the target lesion.
Time frame: 12 months
Primary Safety Endpoint
The primary safety endpoint is the freedom from ALL of the following adverse events: * All-cause perioperative death (POD) \[evaluated at 30 days\] and * Target limb major (above-the-ankle) amputation \[evaluated at 12 months\] and * Clinically driven target lesion revascularization (CD-TLR) \[evaluated at 12 months\]
Time frame: 30 days or 12 months
PK Sub-Study Primary Endpoint
The primary endpoints of the sub-study are the PK parameters of C(max), T(max), AUC(last), and MRT(last) that will be used to determine the pharmacokinetic profile of Sirolimus after administration of the SELUTION SLR 018 DEB.
Time frame: 6 months
Powered Secondary Endpoints
If both primary endpoints are met, the following endpoint will be tested for superiority in a sequential manner: • Clinically driven target lesion revascularization (CD-TLR) \[evaluated at 12 months\]
Time frame: 12 months
Secondary Performance Endpoints
* Device success, defined as successful delivery, balloon inflation, deflation, and retrieval of the intact investigational device \[evaluated post-procedure\]. * Procedural (technical) success, defined as device success and residual diameter stenosis ≤ 30% on completion angiography by core lab assessment \[evaluated post-procedure\]. * Clinical success, defined as procedural success without procedural complications (death, above-ankle target limb amputation, thrombosis of the target lesion or TLR) prior to discharge (evaluated at discharge defined as immediately prior to hospital discharge from the index procedure or within 7 days, whichever occurs first).
Time frame: Immediately following the procedure
Secondary Safety Endpoints
* Major adverse limb events (MALE): Major adverse limb events (MALE), defined as the composite of major (above-the-ankle) amputation or major reintervention (new bypass graft, jump/interposition graft revision, thrombectomy/thrombolysis) of the index limb. * Major cardiovascular events: defined as the composite of cardiovascular death, myocardial infarction (MI), and stroke. * All-cause mortality. * Major amputation, defined as above-the-ankle amputation of the target limb. * Amputation-free survival, defined as freedom from all-cause mortality and major amputation. * Target lesion thrombosis by angiographic or DUS core laboratory adjudication
Time frame: 1, 6, and 12 months, and 2-5 years
Secondary Efficacy Endpoints
The following exploratory secondary endpoints will be assessed at discharge and at 1, 6, and 12 months, and 2-5 years (unless otherwise indicated). Detailed descriptions of these endpoints are provided individually under the corresponding Secondary Outcome Measures: * Primary sustained clinical improvement * Secondary sustained clinical improvement * Lesion primary patency * Lesion Primary assisted patency * Lesion secondary-assisted patency * Freedom from CD-TLR and binary restenosis * Any TLR * CD-TLR * Clinically driven Target Vessel Revascularization (TVR) * Change in Rutherford category * Change in ankle brachial index (ABI) * Change in Walking capacity assessed by Walking Impairment Questionnaire (WIQ)
Time frame: 1, 6, and 12 months, and 2-5 years
Primary sustained clinical improvement
A secondary efficacy endpoint defined as freedom from target limb major amputation and CD-TLR AND increase in Rutherford category from baseline.
Time frame: 1, 6, and 12 months, and 2-5 years
Secondary sustained clinical improvement
A secondary efficacy endpoint defined as freedom from target limb major amputation AND increase in Rutherford category from baseline. * Major amputation, defined as above-the-ankle amputation of the target limb. * Amputation-free survival, defined as freedom from all-cause mortality and major amputation.
Time frame: 1, 6, and 12 months, and 2-5 years
Lesion primary patency
A secondary efficacy endpoint defined as freedom from lesion re-intervention AND freedom from a DS \>50% restenosis assessed by Core Lab, using by order of preference (1) angiography, (2) CT, (3) MRA, (4) DUS (as determined by a DUS peak systolic velocity ratio \[PSVR\] of ≤ 2.4)
Time frame: 1, 6, and 12 months, and 2-5 years
Lesion Primary assisted patency
A secondary efficacy endpoint defined as freedom from a DS\>50% restenosis assessed by Core Lab, using by order of preference (1) angiography, (2) CT, (3) MRA, (4) DUS (as determined by a DUS peak systolic velocity ratio PSVR of ≤ 2.4) - irrespective of interventions for stenoses. Lesion Secondary patency, defined as freedom from lesion re-intervention, AND freedom from permanent occlusion (at the last follow-up imaging) assessed by Core Lab, using by order of preference (1) angiography, (2) CT, (3) MRA, (4) DUS.
Time frame: 1, 6, and 12 months, and 2-5 years
Lesion secondary-assisted patency
A secondary efficacy endpoint defined as freedom from permanent occlusion (at the last follow-up imaging) assessed by Core Lab, using by order of preference (1) angiography, (2) CT, (3) MRA, (4) DUS - irrespective of interventions for stenoses
Time frame: 12 and 24 months
Freedom from CD-TLR and binary restenosis
A secondary efficacy endpoint as determined by the DCL \[at 1, 3, 6, 12, 24, 36 months\]
Time frame: 1, 3, 6, 12, 24, 36 months
Any TLR
A secondary efficacy endpoint defined as any re-intervention of target lesion(s).
Time frame: 1, 6, and 12 months, and 2-5 years
CD-TLR
A secondary efficacy endpoint defined as re-intervention of target lesion(s) due to recurrent/persistent/worsening symptoms and the angiographic finding of ≥ 50% restenosis of target lesion by ACL measurement.
Time frame: 1, 6, and 12 months, and 2-5 years
Clinically driven Target Vessel Revascularization (TVR)
A secondary efficacy endpoint defined as re-intervention of target vessel due to recurrent/persistent/worsening symptoms and the angiographic finding of ≥ 50% restenosis of target vessel by ACL measurement.
Time frame: 1, 6, and 12 months, and 2-5 years
Change in Rutherford category
A secondary efficacy endpoint from baseline \[at 1, 6, 12, 24 and 36 months\]
Time frame: 1, 6, 12, 24 and 36 months
Change in ankle brachial index (ABI)
A secondary efficacy endpoint defined as change in ankle brachial index (ABI) from baseline.
Time frame: 12 and 24 months
Change in Walking capacity assessed by Walking Impairment Questionnaire (WIQ)
A secondary efficacy endpoint defined as change in Walking capacity assessed by Walking Impairment Questionnaire (WIQ) from baseline.
Time frame: 1, 6, 12, 24 and 36 months
Secondary Imaging endpoints (DCL adjudicated):
* Primary duplex-defined binary restenosis - Peak Systolic Velocity Ratio (PSVR)\>2.4. * Alternate duplex-defined binary restenosis - Peak Systolic Velocity Ratio (PSVR)\>3.4.
Time frame: 12 and 24 months
Secondary Quality of life and health economic assessments (1)
• Change in EQ-5D score from baseline. OBS.: Following EuroQol terminology: Scores are anchored at 1 (full health) and 0 (a state as bad as being dead) as required by their use in economic evaluation. Values less than 0 represent health states regarded as worse than a state that is as bad as being dead.
Time frame: 12 months
Secondary Quality of life and health economic assessments (2)
• Days of target lesion-related hospitalization at 12 months.
Time frame: 12 months
PK Sub-Study Secondary Endpoint
If calculations are valid, additional PK parameters of AUC(inf), Cl, Vz, Vss, and half-life. Other PK parameters such as dose normalized Cmax and AUC will be considered if appropriate.
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2022 to primary completion in Jul 2026, 43 months.
Of 125 industry-sponsored interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's 43 months is above that.
Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.
Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jul 2026, on Nov 4, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
M.A. Med Alliance S.A.